Cartesian Therapeutics, Inc. SEC filings RNAC
Cartesian Therapeutics, Inc. has 876 filings in SEC EDGAR's recent list, going back to Jan 5, 2009. Its latest annual report, Form 10-K, was filed on Mar 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Apr 28, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 28, 2025 | — |
| DEF 14A | Proxy statement | Aug 16, 2024 | Sep 20, 2024 |
| PRE 14A | Preliminary proxy statement | Aug 2, 2024 | Aug 2, 2024 |
| DEF 14A | Proxy statement | Apr 26, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEFA14A | Additional proxy material | Feb 14, 2024 | — |
| DEF 14A | Proxy statement | Feb 14, 2024 | Feb 14, 2024 |
| PRE 14A | Preliminary proxy statement | Jan 31, 2024 | Jan 31, 2024 |
| DEFA14A | Additional proxy material | Nov 13, 2023 | — |
| DEFA14A | Additional proxy material | Jun 13, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | — |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| PRE 14A | Preliminary proxy statement | Apr 18, 2023 | — |
| DEF 14A | Proxy statement | May 3, 2022 | Dec 31, 2021 |
| DEFA14A | Additional proxy material | May 3, 2022 | — |
| PRE 14A | Preliminary proxy statement | Apr 22, 2022 | Dec 31, 2021 |
| DEF 14A | Proxy statement | Apr 22, 2022 | Dec 31, 2021 |
| DEF 14A | Proxy statement | Apr 29, 2021 | Apr 29, 2021 |
| DEFA14A | Additional proxy material | Apr 29, 2021 | — |
| DEF 14A | Proxy statement | Apr 28, 2020 | Dec 31, 2019 |
| DEFA14A | Additional proxy material | Apr 28, 2020 | — |
| DEFA14A | Additional proxy material | Apr 29, 2019 | — |
| DEF 14A | Proxy statement | Apr 29, 2019 | Dec 31, 2018 |
| DEFA14A | Additional proxy material | Apr 25, 2018 | — |
| DEF 14A | Proxy statement | Apr 25, 2018 | Apr 25, 2018 |
| DEFA14A | Additional proxy material | Apr 25, 2017 | — |
| DEF 14A | Proxy statement | Apr 25, 2017 | Jun 16, 2017 |
Showing 30 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RNAC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Frederick, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1453687
- Former names
- SELECTA BIOSCIENCES INC (until Nov 13, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.